Known targets — ChEMBL curated mechanism
CSF1RFLT1FLT4KDRKITPDGFRAPDGFRB
The experimentally established mechanism targets of Vatalanib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 known ✓ | P17948 | 19/20 | 1.00 |
| ▸ | KDR known ✓ | P35968 | 19/20 | 1.00 |
| ▸ | PDGFRB known ✓ | P09619 | 9/20 | 1.00 |
| ▸ | KIT known ✓ | P10721 | 8/20 | 1.00 |
| ▸ | CSF1R known ✓ | P07333 | 2/20 | 1.00 |
| ▸ | FLT4 known ✓ | P35916 | 2/20 | 1.00 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 1.00 |
| ▸ | CIT | O14578 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | HLA-A | P04439 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 1.00 |
| ▸ | FRK | P42685 | 1/20 | 1.00 |
| ▸ | CDK8 | P49336 | 1/20 | 1.00 |
| ▸ | DDR1 | Q08345 | 1/20 | 1.00 |
| ▸ | STK3 | Q13188 | 1/20 | 1.00 |
| ▸ | PTK6 | Q13882 | 1/20 | 1.00 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 1.00 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 1.00 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vatalanib SCHEMBL29350047 | 1.00 | FLT1 (1.00) | FLT1KDRPDGFRBKITCSF1R | |
| Vatalanib SCHEMBL28147347 | 0.99 | FLT1 (0.97) | FLT1KDRPDGFRBKITCSF1R | |
| Vatalanib SCHEMBL6131017 | 0.99 | FLT1 (0.97) | FLT1KDRPDGFRBKITCSF1R | |
| Vatalanib SCHEMBL905598 | 0.99 | FLT1 (0.97) | FLT1KDRPDGFRBKITCSF1R | |
| Vatalanib SCHEMBL6131019 | 0.99 | FLT1 (0.97) | FLT1KDRPDGFRBKITCSF1R | |
| Vatalanib SCHEMBL905616 | 0.99 | FLT1 (0.97) | FLT1KDRPDGFRBKITCSF1R | |
| Vatalanib SCHEMBL6131018 | 0.99 | FLT1 (0.97) | FLT1KDRPDGFRBKITCSF1R | |
| Vatalanib SCHEMBL29633763 | 0.99 | FLT1 (0.97) | FLT1KDRPDGFRBKITCSF1R | |
| Vatalanib SCHEMBL6605579 | 0.93 | KDR (0.88) | FLT1KDRPDGFRBKITCSF1R | |
| Vatalanib SCHEMBL6607537 | 0.92 | KDR (0.84) | FLT1KDRPDGFRBKITCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4301 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200163877-A1 | LIPOSOME FORMULATIONS | OPKO PHARMACEUTICALS, LLC. | 2020-05-28 | — | — | US | claimed |
| US-20190321467-A1 | LIPOSOME FORMULATIONS | OPKO PHARMACEUTICALS, LLC. | 2019-10-24 | — | — | US | claimed |
| EP-3519558-A1 | USE OF ENGINEERED RENAL TISSUES IN ASSAYS | Organovo, Inc. (US) | 2019-08-07 | — | — | EP | claimed |
| EP-2805945-B1 | Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors | MSD ITALIA SRL (IT) | 2019-04-03 | — | — | EP | claimed |
| WO-2018064323-A1 | USE OF ENGINEERED RENAL TISSUES IN ASSAYS | ORGANOVO, INC. (US) | 2018-04-05 | — | — | WO | claimed |
| EP-2676953-B1 | HEMIFUMARATE SALT OF 1-[4-[1-(4-CYCLOHEXYL-3 -TRIFLUOROMETHYL-BENZYLOXYIMINO)-ETHYL]-2-ETHYL-BENZYL]-AZETIDINE-3-CARBOXYLIC ACID FOR USE IN THE TREATMENT OF LYMPHOCYTE MEDIATED DISEASES | NOVARTIS AG (CH) | 2017-03-22 | — | — | EP | claimed |
| EP-1633336-B1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | NOVARTIS AG (CH) | 2016-06-22 | — | — | EP | claimed |
| US-20150224055-A1 | LIPOSOME FORMULATIONS | OPKO PHARMACEUTICALS, LLC | 2015-08-13 | — | — | US | claimed |
| US-20140301976-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. | 2014-10-09 | — | — | US | claimed |
| US-8779171-B2 | Hydroxamates as therapeutic agents | PHARMACYCLICS, INC. (US) | 2014-07-15 | — | — | US | claimed |
| EP-1250140-A2 | COMBINATIONS OF A RECEPTOR TYROSINE KINASE INHIBITOR WITH ALPHA1-ACIDIC GLYCOPROTEIN BINDING COMPOUND | Novartis AG (CH) | 2002-10-23 | — | — | EP | claimed |
| CN-1367695-A | Phthalazine derivatives for the treatment of inflammatory diseases | NOVARTIS AG (CH) | 2002-09-04 | — | — | CN | claimed |
| US-20020091261-A1 | Phthalazines with angiogenesis inhibiting activity | BOLD GUIDO (CH) | 2002-07-11 | — | — | US | claimed |
| EP-1165085-A1 | PHTHALAZINE DERIVATIVES FOR TREATING INFLAMMATORY DISEASES | Novartis AG (CH) | 2002-01-02 | — | — | EP | claimed |
| WO-2001097850-A2 | COMBINATIONS AND COMPOSITIONS WHICH INTERFERE WITH VEGF/VEGF AND ANGIOPOIETIN/TIE RECEPTOR FUNCTION AND THEIR USE (II) | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-12-27 | — | — | WO | claimed |
| US-6258812-B1 | ANGIOGENESIS INHIBITORS, ANTITUMOR AGENTS AND CARDIOVASCULAR DISORDERS | NOVARTIS AG (CH) | 2001-07-10 | — | — | US | claimed |
| WO-2001047507-A2 | COMBINATIONS OF RECEPTOR TYROSINE KINASE INHIBITOR WITH AN A1-ACIDIC GLYCOPROTEIN BINDING COMPOUND | NOVARTIS AG (CH) | 2001-07-05 | — | — | WO | claimed |
| WO-2000059509-A1 | PHTHALAZINE DERIVATIVES FOR TREATING INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2000-10-12 | — | — | WO | claimed |
| EP-0970070-A1 | PHTHALAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | Novartis AG (CH) | 2000-01-12 | — | — | EP | claimed |
| WO-1998035958-A1 | PHTHALAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | NOVARTIS AG (CH) | 1998-08-20 | — | — | WO | claimed |